Strategic Signals Weekly

Caribou Biosciences is exploring strategic alternatives, including a potential merger or acquisition, to maximize stockholder value and has engaged Wedbush Securities Inc. as its financial advisor. Concurrently, the company is discontinuing further development of its allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (vispa-cel) and CB-011, which were in Phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, respectively. This restructuring includes a significant workforce reduction and is expected to incur $15 million to $19 million in related expenses.

Regeneron Pharmaceuticals and Sanofi amended their collaboration agreement to co-develop and co-commercialize four new Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13. Sanofi will make an upfront payment of $1.0 billion to Regeneron, with potential for an additional $7.0 billion in development, regulatory, and commercial milestones. Regeneron also gained an option to include Sanofi's Phase 2/3 asset lunsekimig and another early development product in the collaboration.

Drug: IL-13 antibody, IL-4 antibody, IL-4Rα antibody, IL-4xIL-13 bispecific antibody · Partner: Sanofi

Harrow, Inc. completed the acquisition of global rights (excluding Japan) to TYRVAYA (varenicline solution) nasal spray from Viatris Inc. for $30.0 million upfront cash and up to $70.0 million in contingent sales milestones. This transaction includes the NDA and related intellectual property for the dry eye disease treatment. Viatris retains Japanese rights and will pay Harrow tiered royalties on sales in that territory.

Drug: TYRVAYA · Indication: dry eye disease · Partner: Viatris Inc.

Alector, Inc. entered into a License Agreement with Genentech, granting Genentech exclusive worldwide rights to develop and commercialize Alector’s AL050 program, an engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive a $100 million upfront payment and is eligible for up to an additional $1.17 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Genentech will be responsible for all development, regulatory, manufacturing, and commercialization activities for the GCase Candidates.

Drug: AL050 (GCase Candidates) · Partner: Genentech

Flyte Aviation, Inc. (formerly Catheter Precision, Inc.) announced a private placement where existing investors agreed to purchase 2,050 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $2.05 million, with closing expected around October 13, 2026. Concurrently, the company reduced the conversion price of its Series C-1, C-2, C-3, C-4, D, and J Convertible Preferred Stock to $1.00 per share.

Vaxcyte, Inc. successfully completed concurrent public offerings, raising approximately $1.103 billion in total net proceeds. This included an equity offering yielding $544.3 million from common stock and pre-funded warrants, and a debt offering of 1.50% Convertible Senior Notes due 2032, which generated $558.7 million.

Integra LifeSciences Holdings Corporation announced the pricing of $450 million aggregate principal amount of 9.500% senior secured notes due 2033 in a private placement. This debt offering is part of the company's debt refinancing plan and is anticipated to increase its effective interest rate by 100-200 basis points, consistent with previous management guidance.

iSpecimen Inc. stockholders approved the issuance of shares underlying Pre-Funded Warrants and for future convertible financing transactions, both potentially exceeding 19.99% of outstanding common stock and at prices below Nasdaq's Minimum Price, to comply with Nasdaq Listing Rule 5635(d). Additionally, an asset acquisition from Foldlab AI Ltd., partially paid with common stock, was approved. The vote on a reverse stock split was adjourned to October 30, 2026, to allow for additional stockholder voting.

Valion Bio, Inc. entered into a letter agreement with 3i, LP, under which 3i agreed to purchase 50 Series B Preferred Shares and warrants for $50,000. This transaction is part of a larger Series B Preferred Purchase Agreement, initially established in April 2025 and amended in December 2025, which provides for an aggregate purchase price of up to $8.4 million in Series B Preferred Shares and warrants.